Jan Smeitink
Research Subjects
Jan Smeitink has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Richard Jt Rodenburg
Radboud Center for Mitochondrial Medicine, Department of Human Genetics Radboud UMC Nijmegen the Netherlands
5 shared publications - Massimo Zeviani
University of Padova
4 shared publications - Peter H. G. M. Willems
Department of Biochemistry (286), Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
4 shared publications - Saskia Koene
Department of Pediatrics, Nijmegen Centre for Mitochondrial Disorders, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
4 shared publications - Cristina Ugalde
Instituto de Investigación Hospital 12 de Octubre (i + 12), Madrid, Spain
3 shared publications - Howard Trevor Jacobs
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
3 shared publications
Latest Publications
- 8 August 2025
- Published by BMJ in BMJ Case Reports
- Vol. 2009
A novel mitochondrial ATP8 gene mutation in a patient with apical hypertrophic cardiomyopathy and neuropathy
To identify the biochemical and molecular genetic defect in a 16-year-old patient presenting with apical hypertrophic cardiomyopathy and neuropathy suspected for a mitochondrial disorder. Measurement of the mitochondrial energy-generating system (MEGS) capacity in muscle and enzyme analysis in muscle and fibroblasts were performed. Relevant parts of the mitochondrial DNA were analysed by sequencing. A homoplasmic nonsense mutation m.8529G→A (p.Trp55X) was found in the mitochondrial ATP8 gene in the patient’s fibroblasts and muscle tissue. Reduced complex V activity was measured in the patient’s fibroblasts and muscle tissue, and was confirmed in cybrid clones containing patient-derived mitochondrial DNA We describe the first pathogenic mutation in the mitochondrial ATP8 gene, resulting in an improper assembly and reduced activity of the complex V holoenzyme.
- 8 August 2025
- Published by BMJ in BMJ Case Reports
- Vol. 2009
A novel mitochondrial ATP8 gene mutation in a patient with apical hypertrophic cardiomyopathy and neuropathy
To identify the biochemical and molecular genetic defect in a 16-year-old patient presenting with apical hypertrophic cardiomyopathy and neuropathy suspected for a mitochondrial disorder. Measurement of the mitochondrial energy-generating system (MEGS) capacity in muscle and enzyme analysis in muscle and fibroblasts were performed. Relevant parts of the mitochondrial DNA were analysed by sequencing. A homoplasmic nonsense mutation m.8529G→A (p.Trp55X) was found in the mitochondrial ATP8 gene in the patient’s fibroblasts and muscle tissue. Reduced complex V activity was measured in the patient’s fibroblasts and muscle tissue, and was confirmed in cybrid clones containing patient-derived mitochondrial DNA We describe the first pathogenic mutation in the mitochondrial ATP8 gene, resulting in an improper assembly and reduced activity of the complex V holoenzyme.
- 1 September 2015
- Published by Elsevier in Mitochondrion
- Vol. 24, S45-S46
Mitochondrial myopathy biomarker Fibroblast growth factor 21 is induced by muscle mtDNA instability and translation defects
- 1 September 2015
- Published by Elsevier in Mitochondrion
- Vol. 24, S45-S46
Mitochondrial myopathy biomarker Fibroblast growth factor 21 is induced by muscle mtDNA instability and translation defects
- 30 July 2015
- Published by IOS Press in Journal of Pediatric Neurology
- Vol. 07 (04) , 345-350
Muscle pain, fatigue and night hypothermia in association with mitochondrial dysfunction
In case of non-specific and relatively mild muscle symptoms, the diagnosis of an inborn error of metabolism could be easily missed. Muscle pain can be the first sign of a mitochondrial disorder, especially in combination with motor developmental delay or associated organ dysfunction. Here we report on six children with a distinctive pattern of symptoms in association with variable, suboptimal mitochondrial dysfunction. This pattern exists of early onset exercise intolerance, fatigue, feeding difficulties and concentration problems associated with recurrent episodes of nocturnal hypothermia, muscle pain and mild motor retardation. No endocrine, cardiac, immunologic, neurodegenerative or psychiatric causes were found to explain these complaints. Based on the presence of muscle pain, multisystem involvement and mild lactic acidemia a mitochondrial disorder was suspected. We found decreased oxidation capacity in muscle, confirming a suboptimal mitochondrial function in our patients. Four out of five patients benefited from high dose riboflavin therapy. We think pediatricians should be aware of the possibility of a mitochondrial dysfunction in children presenting with a combination of diverse but relatively mild, “aspecific” symptoms. We advise to use the Mitochondrial Disease Criteria to evaluate the possibility of mitochondrial disease in these children.
- 30 July 2015
- Published by IOS Press in Journal of Pediatric Neurology
- Vol. 07 (04) , 345-350
Muscle pain, fatigue and night hypothermia in association with mitochondrial dysfunction
In case of non-specific and relatively mild muscle symptoms, the diagnosis of an inborn error of metabolism could be easily missed. Muscle pain can be the first sign of a mitochondrial disorder, especially in combination with motor developmental delay or associated organ dysfunction. Here we report on six children with a distinctive pattern of symptoms in association with variable, suboptimal mitochondrial dysfunction. This pattern exists of early onset exercise intolerance, fatigue, feeding difficulties and concentration problems associated with recurrent episodes of nocturnal hypothermia, muscle pain and mild motor retardation. No endocrine, cardiac, immunologic, neurodegenerative or psychiatric causes were found to explain these complaints. Based on the presence of muscle pain, multisystem involvement and mild lactic acidemia a mitochondrial disorder was suspected. We found decreased oxidation capacity in muscle, confirming a suboptimal mitochondrial function in our patients. Four out of five patients benefited from high dose riboflavin therapy. We think pediatricians should be aware of the possibility of a mitochondrial dysfunction in children presenting with a combination of diverse but relatively mild, “aspecific” symptoms. We advise to use the Mitochondrial Disease Criteria to evaluate the possibility of mitochondrial disease in these children.
- 1 November 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (6) , 939-940
FBXL4 is a mitochondria-localized protein in which autosomal recessive mutations cause multiple respiratory chain multisystem disease commonly involving cortical atrophy and leukodystrophy
- 1 November 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (6) , 939-940
FBXL4 is a mitochondria-localized protein in which autosomal recessive mutations cause multiple respiratory chain multisystem disease commonly involving cortical atrophy and leukodystrophy
- 1 November 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (6) , 899-900
Six minute bicycling test in children with mitochondrial disorders: Feasibility, reliability, validity and responsivity
- 1 November 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (6) , 899-900
Six minute bicycling test in children with mitochondrial disorders: Feasibility, reliability, validity and responsivity
- 30 September 2012
- Published by Elsevier in Mitochondrion
- Vol. 12 (5) , 550-551
Optimizing patient care and outcome measures: which complaints are most burdensome to patients and their parents?
- 30 September 2012
- Published by Elsevier in Mitochondrion
- Vol. 12 (5) , 550-551
Optimizing patient care and outcome measures: which complaints are most burdensome to patients and their parents?
- Open Access
- 2 March 2011
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2) , 247-248
Mitochondrial medicine
- 2 March 2011
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2) , 247-248
Open AccessMitochondrial medicine
- 31 July 2010
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1797, 51
Molecular studies of Polish patients with respiratory chain complex I deficiency
- 31 July 2010
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Bioenergetics
- Vol. 1797, 51
Molecular studies of Polish patients with respiratory chain complex I deficiency
- Open Access
- 29 July 2010
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2) , 315-325
Metabolic manipulators: a well founded strategy to combat mitochondrial dysfunction
Whilst the pathophysiology and genetics of mitochondrial disease are slowly being unraveled, currently no effective remedy for mitochondrial disorders is available. One particular strategy in mitocho...
- 29 July 2010
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2) , 315-325
Open AccessMetabolic manipulators: a well founded strategy to combat mitochondrial dysfunction
Whilst the pathophysiology and genetics of mitochondrial disease are slowly being unraveled, currently no effective remedy for mitochondrial disorders is available. One particular strategy in mitocho...
- 27 January 2010
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2) , 293-307
Mouse models for nuclear DNA‐encoded mitochondrial complex I deficiency
Mitochondrial diseases are a group of heterogeneous pathologies with decreased cellular energy production as a common denominator. Defects in the oxidative phosphorylation (OXPHOS) system, the most frequent one in humans being isolated complex I deficiency (OMIM 252010), underlie this disturbed‐energy generation. As biogenesis of OXPHOS complexes is under dual genetic control, with complex II being the sole exception, mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) are found. Increasing knowledge is becoming available with respect to the pathophysiology and cellular consequences of OXPHOS dysfunction. This aids the rational design of new treatment strategies. Recently, the first successful treatment trials were carried out in patient‐derived cell lines. In these studies chemical compounds were used that target cellular aberrations induced by complex I dysfunction. Before the field of human clinical trials is entered, it is necessary to study the effects of these compounds with respect to toxicity, pharmacokinetics and therapeutic potential in suitable animal models. Here, we discuss two recent mouse models for nDNA‐encoded complex I deficiency and their tissue‐specific knock‐outs.
- 27 January 2010
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2) , 293-307
Mouse models for nuclear DNA‐encoded mitochondrial complex I deficiency
Mitochondrial diseases are a group of heterogeneous pathologies with decreased cellular energy production as a common denominator. Defects in the oxidative phosphorylation (OXPHOS) system, the most frequent one in humans being isolated complex I deficiency (OMIM 252010), underlie this disturbed‐energy generation. As biogenesis of OXPHOS complexes is under dual genetic control, with complex II being the sole exception, mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) are found. Increasing knowledge is becoming available with respect to the pathophysiology and cellular consequences of OXPHOS dysfunction. This aids the rational design of new treatment strategies. Recently, the first successful treatment trials were carried out in patient‐derived cell lines. In these studies chemical compounds were used that target cellular aberrations induced by complex I dysfunction. Before the field of human clinical trials is entered, it is necessary to study the effects of these compounds with respect to toxicity, pharmacokinetics and therapeutic potential in suitable animal models. Here, we discuss two recent mouse models for nDNA‐encoded complex I deficiency and their tissue‐specific knock‐outs.